Modeling Interventions to Reduce the Spread of Multidrug-Resistant Organisms Between Health Care Facilities in a Region.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
02 08 2021
02 08 2021
Historique:
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
11
1
2022
Statut:
epublish
Résumé
Multidrug-resistant organisms (MDROs) can spread across health care facilities in a region. Because of limited resources, certain interventions can be implemented in only some facilities; thus, decision-makers need to evaluate which interventions may be best to implement. To identify a group of target facilities and assess which MDRO intervention would be best to implement in the Shared Healthcare Intervention to Eliminate Life-threatening Dissemination of MDROs in Orange County, a large regional public health collaborative in Orange County, California. An agent-based model of health care facilities was developed in 2016 to simulate the spread of methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE) for 10 years starting in 2010 and to simulate the use of various MDRO interventions for 3 years starting in 2017. All health care facilities (23 hospitals, 5 long-term acute care hospitals, and 74 nursing homes) serving adult inpatients in Orange County, California, were included, and 42 target facilities were identified via network analyses. Increasing contact precaution effectiveness, increasing interfacility communication about patients' MDRO status, and performing decolonization using antiseptic bathing soap and a nasal product in a specific group of target facilities. MRSA and CRE prevalence and number of new carriers (ie, transmission events). Compared with continuing infection control measures used in Orange County as of 2017, increasing contact precaution effectiveness from 40% to 64% in 42 target facilities yielded relative reductions of 0.8% (range, 0.5%-1.1%) in MRSA prevalence and 2.4% (range, 0.8%-4.6%) in CRE prevalence in health care facilities countywide after 3 years, averting 761 new MRSA transmission events (95% CI, 756-765 events) and 166 new CRE transmission events (95% CI, 158-174 events). Increasing interfacility communication of patients' MDRO status to 80% in these target facilities produced no changes in the prevalence or transmission of MRDOs. Implementing decolonization procedures (clearance probability: 39% in hospitals, 27% in long-term acute care facilities, and 3% in nursing homes) yielded a relative reduction of 23.7% (range, 23.5%-23.9%) in MRSA prevalence, averting 3515 new transmission events (95% CI, 3509-3521 events). Increasing the effectiveness of antiseptic bathing soap to 48% yielded a relative reduction of 39.9% (range, 38.5%-41.5%) in CRE prevalence, averting 1435 new transmission events (95% CI, 1427-1442 events). The findings of this study highlight the ways in which modeling can inform design of regional interventions and suggested that decolonization would be the best strategy for the Shared Healthcare Intervention to Eliminate Life-threatening Dissemination of MDROs in Orange County.
Identifiants
pubmed: 34347060
pii: 2782668
doi: 10.1001/jamanetworkopen.2021.19212
pmc: PMC8339938
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2119212Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM127512
Pays : United States
Références
MMWR Morb Mortal Wkly Rep. 2015 Aug 7;64(30):826-31
pubmed: 26247436
Health Aff (Millwood). 2012 Oct;31(10):2295-303
pubmed: 23048111
Am J Infect Control. 2004 Dec;32(8):451-5
pubmed: 15573051
Clin Orthop Relat Res. 2016 Jul;474(7):1592-8
pubmed: 26956247
Infect Control Hosp Epidemiol. 2008 Sep;29(9):785-814
pubmed: 18767983
Am J Epidemiol. 2016 Mar 1;183(5):480-9
pubmed: 26872710
Am J Public Health. 2011 Apr;101(4):707-13
pubmed: 21330578
J Arthroplasty. 2012 Jun;27(6):870-6
pubmed: 22397861
Am J Infect Control. 2010 Mar;38(2):105-11
pubmed: 19913329
Antimicrob Resist Infect Control. 2015 Dec 18;4:56
pubmed: 26688720
J Med Econ. 2013;16(2):264-77
pubmed: 23173567
Am J Infect Control. 2008 Sep;36(7):504-35
pubmed: 18786461
Antimicrob Agents Chemother. 1999 Jun;43(6):1412-6
pubmed: 10348762
Clin Infect Dis. 2020 Dec 3;71(9):2527-2532
pubmed: 32155235
Am J Infect Control. 2015 Jun;43(6):577-80
pubmed: 25681303
Am J Epidemiol. 2016 Mar 1;183(5):471-9
pubmed: 26861238
Infection. 2014 Jun;42(3):493-502
pubmed: 24464791
Infect Control Hosp Epidemiol. 2013 Feb;34(2):151-60
pubmed: 23295561
Infect Control Hosp Epidemiol. 2015 Jul;36(7):759-66
pubmed: 25797334
J Am Med Dir Assoc. 2020 Dec;21(12):1937-1943.e2
pubmed: 32553489
Curr Infect Dis Rep. 2017 Apr;19(4):18
pubmed: 28382547
Infect Control Hosp Epidemiol. 2011 Jun;32(6):562-72
pubmed: 21558768
Infect Control Hosp Epidemiol. 2007 Mar;28(3):358-61
pubmed: 17326031
Infect Control Hosp Epidemiol. 2018 Sep;39(9):1049-1057
pubmed: 30037355
Clin Infect Dis. 2007 Jan 15;44(2):178-85
pubmed: 17173213
Clin Infect Dis. 2008 Apr 15;46(8):1139-41
pubmed: 18444847
Clin Infect Dis. 2021 Feb 1;72(3):438-447
pubmed: 31970389
Med Clin (Barc). 2019 Mar 15;152(6):222-225
pubmed: 29779567
Infect Control Hosp Epidemiol. 2010 Nov;31(11):1160-9
pubmed: 20874503
Clin Infect Dis. 2019 Oct 15;69(9):1566-1573
pubmed: 30753383
J Hosp Infect. 2019 Nov;103(3):235-243
pubmed: 31494130
Clin Infect Dis. 2019 Jan 1;68(1):22-28
pubmed: 29762662
Am J Infect Control. 2007 Dec;35(10):650-5
pubmed: 18063129
Clin Infect Dis. 2020 Feb 14;70(5):843-849
pubmed: 31070719
Infect Control Hosp Epidemiol. 2014 Sep;35 Suppl 2:S108-32
pubmed: 25376072
Infect Control Hosp Epidemiol. 2018 May;39(5):516-524
pubmed: 29552995
J Infect Dis. 2020 May 11;221(11):1782-1794
pubmed: 31150539
Clin Microbiol Infect. 2014 Oct;20(10):973-80
pubmed: 25273968
Crit Care Nurse. 2014 Oct;34(5):17-25; quiz 26
pubmed: 25274761
Med Care. 2013 Mar;51(3):205-15
pubmed: 23358388
PLoS One. 2011;6(12):e29342
pubmed: 22216255
Clin Infect Dis. 2015 Apr 15;60(8):1153-61
pubmed: 25537877
Clin Infect Dis. 2006 Feb 1;42(3):370-6
pubmed: 16392083
J Antimicrob Chemother. 2011 Oct;66(10):2409-17
pubmed: 21719473
JAMA Netw Open. 2020 Aug 3;3(8):e2012522
pubmed: 32789514
Am J Infect Control. 2013 Aug;41(8):668-73
pubmed: 23896284
Clin Microbiol Infect. 2017 Jan;23(1):48.e9-48.e16
pubmed: 27642178